Navigation Links
Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
Date:11/27/2007

CALGARY, Nov. 27 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) ("Oncolytics") today announced that it has been granted U.S. Patent 7,300,650 entitled "Reovirus for the Treatment of Neoplasia." The claims describe methods of using the reovirus to treat cancers that have inactivated PKR, whether the PKR is inactivated by mutation of Ras or by other factors. PKR is a host cellular protein responsible for preventing virus replication within a cell. Tumour cells lacking the activity of PKR are susceptible to reovirus replication and subsequently, cancer cell killing.

"This patent represents a significant expansion of our intellectual property portfolio," said Dr. Matt Coffey, Chief Scientific Officer of Oncolytics. "The claims cover additional pathways whereby tumours can become susceptible to reovirus infection and cell death."

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com.

This news release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including among others, the Company's belief as to the importance of the issuance of this patent, the safety and efficacy of the reovirus, the Company's expectations as to the potential applications of the patented technology and other statements relating to anticipated developments in the Company's business and technologies, involve known and unknown risks and uncertainties that could cause the Company
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
11. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced ... Executive Officer of Neurocrine Biosciences, will be presenting at ... The live presentation takes place on Tuesday, March ... be webcast and may be accessed on the Company,s ... are encouraged to visit the website approximately 5 minutes ...
(Date:3/3/2015)... SEATTLE , March 3, 2015 Adaptive ... Group CFO, is joining its Board of Director as ... financial officer at Zillow Group, Chad oversees all finance, ... Chad built the company,s core finance, treasury and accounting ... IPO and nine acquisitions. In 2013, he was named ...
(Date:3/3/2015)... March 03, 2015 Crown Bioscience, Inc., ... has launched a new Life Science division specializing in ... research. , The first products released include in ... and soon to be released in vivo grade monoclonal ... to expand their life science portfolio with additional antibody ...
(Date:3/3/2015)... Fried, Frank, Harris, Shriver & Jacobson LLP ... joined the Firm as a partner in the Intellectual ... York office. Mr. Lewis concentrates on patent ... other intellectual property and general litigation. A trained chemical ... plaintiffs and defendants in a range of technology-related sectors ...
Breaking Biology Technology:Adaptive Biotechnologies adds Chad Cohen, Zillow Group CFO, to Board of Directors 2Crown Bioscience Launches Life Science Product Catalog 2Leading Patent Attorney Jeffrey Lewis Joins Fried Frank's Intellectual Property Litigation Practice 2Leading Patent Attorney Jeffrey Lewis Joins Fried Frank's Intellectual Property Litigation Practice 3
... ... Screening Capabilities Yield High-quality Data for the Broad Institute,s NIH-funded Molecular Libraries and Imaging ... Lexington, ... leading provider of in silico solutions for pharmaceutical R&D and related life sciences, today ...
... Oct. 5 Verenium Corporation (Nasdaq: VRNMD ), ... and high-performance specialty enzymes, today announced that it intends ... shares of its common stock, and potentially warrants, in ... to price before 9:30 am EDT on Tuesday, October ...
... UPPSALA, Sweden, October 5 , ... - At One Sixth the Price of QuanTyper(TM) Without Loss ... to Rapidly Penetrate the Market , AlphaHelix ... - AmpXpress(TM) - to meet demands for lower,instrument prices. This was ...
Cached Biology Technology:Genedata Screener Supports Small Molecule Research at the Broad Institute of Harvard and MIT 2Genedata Screener Supports Small Molecule Research at the Broad Institute of Harvard and MIT 3Genedata Screener Supports Small Molecule Research at the Broad Institute of Harvard and MIT 4Verenium Announces Proposed Public Offering of Common Stock 2Verenium Announces Proposed Public Offering of Common Stock 3AlphaHelix Presents AmpXpress(TM) at the BIOTECHNICA Show 2
(Date:2/11/2015)... 2015 According to ... Market by Product (Cards and Readers, Biometrics, Controllers, Management ... Industrial, Healthcare, Education) and By Geography - Global Forecast and Analysis ... Access Control Market is expected to reach ... CAGR of 10.6% between 2014 and 2020. ...
(Date:2/5/2015)... TRIANGLE PARK, N.C. , Feb. 5, 2015 /PRNewswire/ ... a specialist logistics company and has launched a new ... only Clinical Logistics Organization (CLO).  The new campaign focuses ... emphasis on patient, protocol and shipments. The ... First , aligns Marken,s priorities with its client,s ...
(Date:2/5/2015)... New Market Research Reports Title ... To 2020 has Been Added to GrandViewReseach.com Report Database ... to reach USD 5.10 billion by 2020, according to ... cameras help identify the site of tissue damage in ... demand in medical imaging applications. They have been extensively ...
Breaking Biology News(10 mins):Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Marken Launches New Patient-Centric Campaign 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3
... evaluated improvements in the end-of-life care in intensive care ... special supplement to Critical Care Medicine, the journal of ... dedicated entirely to end-of-life care in the critical care ... critically ill and dying patients in the ICU remains ...
... tropics than in the temperate regions of the globe? Many ... than half), but the reason has been debated for more ... climatic factors somehow cause species to originate more quickly in ... of The American Naturalist, John Wiens and a group of ...
... things may indeed come in small packages for scientists ... The challenge is to analyze material that is smaller ... refined version of nuclear magnetic resonance technology, or NMR, ... venom taken from spindly insects called common two-stripe walking ...
Cached Biology News:End-of-life care can be improved 2End-of-life care can be improved 3More species in the tropics because species have been there longer 2One-of-a-kind imaging probe reveals secrets useful for drug discovery 2One-of-a-kind imaging probe reveals secrets useful for drug discovery 3
NovaScreen offers cell biology, cell culture and molecular biology services for companies who lack a cell culture facility....
... Life Sciences provides cost effective cell culture ... or monoclonal antibodies. Quality at a reasonable ... you require research or commercial product, we ... methods such as roller bottles, hollow fiber, ...
Standard and modified oligonucleotides up to 150 nt-long at any scale for broad applications. Price starts from 30p/base (10 nmole scale)....
... cDNA normalization is essential for ... using high-throughput approaches, such as EST ... Most normalization methods are not well ... cDNA. The Evrogen TRIMMER kit, though, ...
Biology Products: